These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
628 related articles for article (PubMed ID: 24222112)
1. ID3 mutations are recurrent events in double-hit B-cell lymphomas. Gebauer N; Bernard V; Feller AC; Merz H Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112 [TBL] [Abstract][Full Text] [Related]
2. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis. Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741 [TBL] [Abstract][Full Text] [Related]
3. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations? Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357 [TBL] [Abstract][Full Text] [Related]
4. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance of 'double-hit' and 'double-expression' lymphomas. Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842 [TBL] [Abstract][Full Text] [Related]
6. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations]. Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242 [TBL] [Abstract][Full Text] [Related]
7. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895 [TBL] [Abstract][Full Text] [Related]
9. MYC rearranged B-cell neoplasms: Impact of genetics on classification. Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Swerdlow SH Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840 [TBL] [Abstract][Full Text] [Related]
11. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Petrich AM; Nabhan C; Smith SM Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588 [TBL] [Abstract][Full Text] [Related]
12. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina. Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma. Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646 [TBL] [Abstract][Full Text] [Related]
15. Flow cytometry is of limited utility in the early identification of "double-hit" B-cell lymphomas. Platt MY; DeLelys ME; Preffer FI; Sohani AR Cytometry B Clin Cytom; 2013 May; 84(3):143-8. PubMed ID: 23341189 [TBL] [Abstract][Full Text] [Related]
16. Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting. Thirunavukkarasu B; Bal A; Prakash G; Malhotra P; Singh H; Das A Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):49-55. PubMed ID: 34456240 [TBL] [Abstract][Full Text] [Related]
17. [Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas]. Gerhard-Hartmann E; Rosenwald A Pathologe; 2020 Nov; 41(6):574-581. PubMed ID: 32909092 [TBL] [Abstract][Full Text] [Related]
18. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384 [TBL] [Abstract][Full Text] [Related]
19. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. Wang W; Hu S; Lu X; Young KH; Medeiros LJ Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391 [TBL] [Abstract][Full Text] [Related]
20. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma. Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]